248 related articles for article (PubMed ID: 20838944)
1. Androgen replacement therapy after prostate cancer treatment.
Khera M
Curr Urol Rep; 2010 Nov; 11(6):393-9. PubMed ID: 20838944
[TBL] [Abstract][Full Text] [Related]
2. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends.
Kaplan AL; Trinh QD; Sun M; Carter SC; Nguyen PL; Shih YT; Marks LS; Hu JC
J Sex Med; 2014 Apr; 11(4):1063-1070. PubMed ID: 24443943
[TBL] [Abstract][Full Text] [Related]
3. Testosterone replacement therapy and the risk of prostate cancer.
Warburton D; Hobaugh C; Wang G; Lin H; Wang R
Asian J Androl; 2015; 17(6):878-81; discussion 880. PubMed ID: 25865848
[TBL] [Abstract][Full Text] [Related]
4. Testosterone replacement therapy in prostate cancer patients: is it safe?
Umbas R; Sugiono M
Acta Med Indones; 2010 Jul; 42(3):171-5. PubMed ID: 20724773
[TBL] [Abstract][Full Text] [Related]
5. Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer.
Kim JW
Investig Clin Urol; 2020 May; 61(3):242-249. PubMed ID: 32377599
[TBL] [Abstract][Full Text] [Related]
6. The Role of Testosterone Therapy in the Setting of Prostate Cancer.
Rodriguez KM; Pastuszak AW; Khera M
Curr Urol Rep; 2018 Jun; 19(8):67. PubMed ID: 29961247
[TBL] [Abstract][Full Text] [Related]
7. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.
Kaplan AL; Lenis AT; Shah A; Rajfer J; Hu JC
J Sex Med; 2015 Feb; 12(2):374-80. PubMed ID: 25496237
[TBL] [Abstract][Full Text] [Related]
8. Testosterone replacement therapy after primary treatment for prostate cancer.
Agarwal PK; Oefelein MG
J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
[TBL] [Abstract][Full Text] [Related]
9. Testosterone therapy in men with prostate cancer: scientific and ethical considerations.
Morgentaler A
J Urol; 2009 Mar; 181(3):972-9. PubMed ID: 19150547
[TBL] [Abstract][Full Text] [Related]
10. Testosterone Therapy in Men With Prostate Cancer.
Kaplan AL; Hu JC; Morgentaler A; Mulhall JP; Schulman CC; Montorsi F
Eur Urol; 2016 May; 69(5):894-903. PubMed ID: 26719015
[TBL] [Abstract][Full Text] [Related]
11. [Prostate carcinoma and testosterone: risks and controversies].
Rhoden EL; Averbeck MA
Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):956-62. PubMed ID: 20126847
[TBL] [Abstract][Full Text] [Related]
12. Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma?
Landau D; Tsakok T; Aylwin S; Hughes S
Clin Endocrinol (Oxf); 2012 Feb; 76(2):179-81. PubMed ID: 21951017
[TBL] [Abstract][Full Text] [Related]
13. A new era of testosterone and prostate cancer: from physiology to clinical implications.
Khera M; Crawford D; Morales A; Salonia A; Morgentaler A
Eur Urol; 2014 Jan; 65(1):115-23. PubMed ID: 24011426
[TBL] [Abstract][Full Text] [Related]
14. Androgen replacement therapy in aging men.
Katz A
Nurse Pract; 2004 Oct; 29(10):58-64. PubMed ID: 15489672
[No Abstract] [Full Text] [Related]
15. Testosterone therapy and prostate carcinoma.
Rhoden EL; Averbeck MA
Curr Urol Rep; 2009 Nov; 10(6):453-9. PubMed ID: 19863857
[TBL] [Abstract][Full Text] [Related]
16. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer.
Meza J; Weaver K; Martin S
Am Fam Physician; 2013 Oct; 88(8):Online. PubMed ID: 24364582
[No Abstract] [Full Text] [Related]
17. Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression: Pro.
Morgentaler A
J Urol; 2016 Oct; 196(4):985-8. PubMed ID: 27449261
[No Abstract] [Full Text] [Related]
18. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
Kaufman J
Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
[TBL] [Abstract][Full Text] [Related]
19. Testosterone Therapy Among Prostate Cancer Survivors.
Nguyen TM; Pastuszak AW
Sex Med Rev; 2016 Oct; 4(4):376-88. PubMed ID: 27474995
[TBL] [Abstract][Full Text] [Related]
20. Testosterone Treatment of Men with Unequivocal Hypogonadism Following Treatment of Organ-Confined Prostate Cancer.
Jones RB; Snyder PJ
Endocr Pract; 2023 Sep; 29(9):723-726. PubMed ID: 37236354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
